Asthma - Pipeline Review, H2 2016

Date: October 26, 2016
Pages: 735
Price:
US$ 2,500.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: A8EEC930D7CEN
Leaflet:

Download PDF Leaflet

Asthma - Pipeline Review, H2 2016
Asthma - Pipeline Review, H2 2016

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Asthma - Pipeline Review, H2 2016, provides an overview of the Asthma (Respiratory) pipeline landscape.

Asthma is a chronic disease involving the airways in the lungs. These airways, or bronchial tubes, allow air to come in and out of the lungs. Symptoms include shortness of breath, chest tightness or pain, chronic coughing and trouble sleeping due to coughing or wheezing. The predisposing factors include family history, overweight, smoking, exposure to exhaust fumes or other types of pollution and exposure to occupational triggers, such as chemicals used in farming, hairdressing and manufacturing. Treatment includes inhaled corticosteroids, leukotriene modifiers, antihistamines and decongestants.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Asthma - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Asthma (Respiratory), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Asthma (Respiratory) pipeline guide also reviews of key players involved in therapeutic development for Asthma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 6, 16, 44, 36, 124, 25 and 2 respectively for Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 1, 24 and 8 molecules, respectively for Asthma.

Asthma (Respiratory) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Asthma (Respiratory).
  • The pipeline guide reviews pipeline therapeutics for Asthma (Respiratory) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Asthma (Respiratory) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Asthma (Respiratory) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Asthma (Respiratory)
Reasons to buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Asthma (Respiratory).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Asthma (Respiratory) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Introduction
Asthma Overview
Therapeutics Development
Asthma - Therapeutics under Development by Companies
Asthma - Therapeutics under Investigation by Universities/Institutes
Asthma - Pipeline Products Glance
Asthma - Products under Development by Companies
Asthma - Products under Investigation by Universities/Institutes
Asthma - Companies Involved in Therapeutics Development
Asthma - Therapeutics Assessment
Drug Profiles
Asthma - Dormant Projects
Asthma - Discontinued Products
Asthma - Product Development Milestones
Appendix 704

LIST OF TABLES

Number of Products under Development for Asthma, H2 2016
Number of Products under Development for Asthma - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Number of Products under Development by Companies, H2 2016 (Contd..1)
Number of Products under Development by Companies, H2 2016 (Contd..2)
Number of Products under Development by Companies, H2 2016 (Contd..3)
Number of Products under Development by Companies, H2 2016 (Contd..4)
Number of Products under Development by Companies, H2 2016 (Contd..5)
Number of Products under Development by Companies, H2 2016 (Contd..6)
Number of Products under Development by Companies, H2 2016 (Contd..7)
Number of Products under Development by Companies, H2 2016 (Contd..8)
Number of Products under Development by Companies, H2 2016 (Contd..9)
Number of Products under Development by Companies, H2 2016 (Contd..10)
Number of Products under Investigation by Universities/Institutes, H2 2016
Number of Products under Investigation by Universities/Institutes, H2 2016 (Contd..1)
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Development, H2 2016
Comparative Analysis by Unknown Stage Development, H2 2016
Products under Development by Companies, H2 2016
Products under Development by Companies, H2 2016 (Contd..1)
Products under Development by Companies, H2 2016 (Contd..2)
Products under Development by Companies, H2 2016 (Contd..3)
Products under Development by Companies, H2 2016 (Contd..4)
Products under Development by Companies, H2 2016 (Contd..5)
Products under Development by Companies, H2 2016 (Contd..6)
Products under Development by Companies, H2 2016 (Contd..7)
Products under Development by Companies, H2 2016 (Contd..8)
Products under Development by Companies, H2 2016 (Contd..9)
Products under Development by Companies, H2 2016 (Contd..10)
Products under Development by Companies, H2 2016 (Contd..11)
Products under Development by Companies, H2 2016 (Contd..12)
Products under Development by Companies, H2 2016 (Contd..13)
Products under Development by Companies, H2 2016 (Contd..14)
Products under Development by Companies, H2 2016 (Contd..15)
Products under Development by Companies, H2 2016 (Contd..16)
Products under Investigation by Universities/Institutes, H2 2016
Products under Investigation by Universities/Institutes, H2 2016 (Contd..1)
Asthma - Pipeline by 4D Pharma Plc, H2 2016
Asthma - Pipeline by AB Science SA, H2 2016
Asthma - Pipeline by AbbVie Inc, H2 2016
Asthma - Pipeline by Abeome Corporation, H2 2016
Asthma - Pipeline by Accolade Pharmaceuticals, LLC, H2 2016
Asthma - Pipeline by Acorda Therapeutics, Inc., H2 2016
Asthma - Pipeline by Adamis Pharmaceuticals Corporation, H2 2016
Asthma - Pipeline by Advinus Therapeutics Ltd, H2 2016
Asthma - Pipeline by Afferent Pharmaceuticals, Inc., H2 2016
Asthma - Pipeline by ALK-Abello A/S, H2 2016
Asthma - Pipeline by Allergopharma GmbH & Co. KG, H2 2016
Asthma - Pipeline by Almirall, S.A., H2 2016
Asthma - Pipeline by Amakem NV, H2 2016
Asthma - Pipeline by Amgen Inc., H2 2016
Asthma - Pipeline by AnaptysBio, Inc., H2 2016
Asthma - Pipeline by AnGes MG, Inc., H2 2016
Asthma - Pipeline by Antisense Therapeutics Limited, H2 2016
Asthma - Pipeline by ARA Healthcare Pvt. Ltd., H2 2016
Asthma - Pipeline by Array BioPharma Inc., H2 2016
Asthma - Pipeline by ASIT biotech s.a., H2 2016
Asthma - Pipeline by Astellas Pharma Inc., H2 2016
Asthma - Pipeline by AstraZeneca Plc, H2 2016
Asthma - Pipeline by Asubio Pharma Co., Ltd., H2 2016
Asthma - Pipeline by Aurigene Discovery Technologies Limited, H2 2016
Asthma - Pipeline by Axikin Pharmaceuticals, Inc., H2 2016
Asthma - Pipeline by Bioncotech Therapeutics SL, H2 2016
Asthma - Pipeline by Biotec Pharmacon ASA, H2 2016
Asthma - Pipeline by Boehringer Ingelheim GmbH, H2 2016
Asthma - Pipeline by CalciMedica, Inc., H2 2016
Asthma - Pipeline by Cellceutix Corporation, H2 2016
Asthma - Pipeline by Cellular Biomedicine Group, Inc., H2 2016
Asthma - Pipeline by Celon Pharma Sp. z o.o., H2 2016
Asthma - Pipeline by Chiesi Farmaceutici SpA, H2 2016
Asthma - Pipeline by Circassia Pharmaceuticals Plc, H2 2016
Asthma - Pipeline by Cognosci, Inc., H2 2016
Asthma - Pipeline by CSL Limited, H2 2016
Asthma - Pipeline by Cumberland Pharmaceuticals, Inc., H2 2016
Asthma - Pipeline by Cynata Therapeutics Limited, H2 2016
Asthma - Pipeline by Daiichi Sankyo Company, Limited, H2 2016
Asthma - Pipeline by F. Hoffmann-La Roche Ltd., H2 2016
Asthma - Pipeline by Foresee Pharmaceuticals, LLC, H2 2016
Asthma - Pipeline by Fountain Biopharma Inc., H2 2016
Asthma - Pipeline by Genentech, Inc., H2 2016
Asthma - Pipeline by GlaxoSmithKline Plc, H2 2016
Asthma - Pipeline by Griffin Discoveries BV, H2 2016
Asthma - Pipeline by Han Wha Pharma Co., Ltd., H2 2016
Asthma - Pipeline by HitGen LTD, H2 2016
Asthma - Pipeline by Hydra Biosciences, Inc., H2 2016
Asthma - Pipeline by iCeutica, Inc., H2 2016
Asthma - Pipeline by iCo Therapeutics Inc., H2 2016
Asthma - Pipeline by Immupharma Plc, H2 2016
Asthma - Pipeline by Infinity Pharmaceuticals, Inc., H2 2016
Asthma - Pipeline by INOXIA Lifesciences GmbH, H2 2016
Asthma - Pipeline by Intech Biopharm Ltd, H2 2016
Asthma - Pipeline by Invion Limited, H2 2016
Asthma - Pipeline by Jiangsu Hansoh Pharmaceutical Co., Ltd., H2 2016
Asthma - Pipeline by Johnson & Johnson, H2 2016
Asthma - Pipeline by Kissei Pharmaceutical Co., Ltd., H2 2016
Asthma - Pipeline by Kolltan Pharmaceuticals, Inc., H2 2016
Asthma - Pipeline by KPI Therapeutics, Inc., H2 2016
Asthma - Pipeline by Kyowa Hakko Kirin Co., Ltd., H2 2016
Asthma - Pipeline by Lead Discovery Center GmbH, H2 2016
Asthma - Pipeline by LegoChem Biosciences, Inc, H2 2016
Asthma - Pipeline by Ligand Pharmaceuticals, Inc., H2 2016
Asthma - Pipeline by Lpath, Inc., H2 2016
Asthma - Pipeline by Mabtech Limited, H2 2016
Asthma - Pipeline by Marinomed Biotechnologie GmbH, H2 2016
Asthma - Pipeline by MedImmune, LLC, H2 2016
Asthma - Pipeline by Merck & Co., Inc., H2 2016
Asthma - Pipeline by Mitsubishi Tanabe Pharma Corporation, H2 2016
Asthma - Pipeline by Mycenax Biotech Inc., H2 2016
Asthma - Pipeline by NAL Pharmaceuticals Ltd., H2 2016
Asthma - Pipeline by NeoPharm Co., Ltd., H2 2016
Asthma - Pipeline by Novartis AG, H2 2016
Asthma - Pipeline by Omeros Corporation, H2 2016
Asthma - Pipeline by Ono Pharmaceutical Co., Ltd., H2 2016
Asthma - Pipeline by OPKO Health, Inc., H2 2016
Asthma - Pipeline by Orbis Biosciences Inc, H2 2016
Asthma - Pipeline by Orion Oyj, H2 2016
Asthma - Pipeline by Oxagen Limited, H2 2016
Asthma - Pipeline by Palatin Technologies, Inc., H2 2016
Asthma - Pipeline by Panacea Biotec Limited, H2 2016
Asthma - Pipeline by Panmira Pharmaceuticals, LLC., H2 2016
Asthma - Pipeline by Paradigm Biopharmaceuticals Limited, H2 2016
Asthma - Pipeline by Peptinnovate Ltd, H2 2016
Asthma - Pipeline by Pfizer Inc., H2 2016
Asthma - Pipeline by PharmaLundensis AB, H2 2016
Asthma - Pipeline by Pharmaxis Limited, H2 2016
Asthma - Pipeline by Pieris Pharmaceuticals Inc, H2 2016
Asthma - Pipeline by Pila Pharma AB, H2 2016
Asthma - Pipeline by Polyphor Ltd., H2 2016
Asthma - Pipeline by Promedior, Inc., H2 2016
Asthma - Pipeline by Prommune, Inc., H2 2016
Asthma - Pipeline by Protectimmun GmbH, H2 2016
Asthma - Pipeline by Prous Institute for Biomedical Research S.A., H2 2016
Asthma - Pipeline by Pulmagen Therapeutics LLP, H2 2016
Asthma - Pipeline by Pulmokine, Inc., H2 2016
Asthma - Pipeline by Re-Pharm Limited, H2 2016
Asthma - Pipeline by Regeneron Pharmaceuticals Inc, H2 2016
Asthma - Pipeline by Respiratorius AB, H2 2016
Asthma - Pipeline by ReveraGen BioPharma, Inc., H2 2016
Asthma - Pipeline by Rhizen Pharmaceuticals S.A., H2 2016
Asthma - Pipeline by Saje Pharma, LLC, H2 2016
Asthma - Pipeline by Shire Plc, H2 2016
Asthma - Pipeline by Spring Bank Pharmaceuticals, Inc., H2 2016
Asthma - Pipeline by Stallergenes Greer plc, H2 2016
Asthma - Pipeline by sterna biologicals Gmbh & Co KG, H2 2016
Asthma - Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H2 2016
Asthma - Pipeline by Sun Pharma Advanced Research Company Ltd., H2 2016
Asthma - Pipeline by Sunovion Pharmaceuticals Inc., H2 2016
Asthma - Pipeline by Swecure AB, H2 2016
Asthma - Pipeline by Synermore Biologics Co Ltd, H2 2016
Asthma - Pipeline by Synovo GmbH, H2 2016
Asthma - Pipeline by Syntrix Biosystems, Inc., H2 2016
Asthma - Pipeline by TaiwanJ Pharmaceuticals Co., Ltd., H2 2016
Asthma - Pipeline by Takeda Pharmaceutical Company Limited, H2 2016
Asthma - Pipeline by Teva Pharmaceutical Industries Ltd., H2 2016
Asthma - Pipeline by The International Biotechnology Center (IBC) Generium, H2 2016
Asthma - Pipeline by Therabron Therapeutics, Inc., H2 2016
Asthma - Pipeline by Theravance Biopharma, Inc., H2 2016
Asthma - Pipeline by Tolerys SA, H2 2016
Asthma - Pipeline by United BioPharma, Inc., H2 2016
Asthma - Pipeline by Vectura Group Plc, H2 2016
Asthma - Pipeline by Verona Pharma Plc, H2 2016
Asthma - Pipeline by WhanIn Pharmaceutical Co., Ltd., H2 2016
Asthma - Pipeline by Xencor, Inc., H2 2016
Asthma - Pipeline by Yungjin Pharm. Co., Ltd., H2 2016
Asthma - Pipeline by Zambon Company S.p.A., H2 2016
Assessment by Monotherapy Products, H2 2016
Assessment by Combination Products, H2 2016
Number of Products by Stage and Target, H2 2016
Number of Products by Stage and Mechanism of Action, H2 2016
Number of Products by Stage and Route of Administration, H2 2016
Number of Products by Stage and Molecule Type, H2 2016
Asthma - Dormant Projects, H2 2016
Asthma - Dormant Projects (Contd..1), H2 2016
Asthma - Dormant Projects (Contd..2), H2 2016
Asthma - Dormant Projects (Contd..3), H2 2016
Asthma - Dormant Projects (Contd..4), H2 2016
Asthma - Dormant Projects (Contd..5), H2 2016
Asthma - Dormant Projects (Contd..6), H2 2016
Asthma - Dormant Projects (Contd..7), H2 2016
Asthma - Dormant Projects (Contd..8), H2 2016
Asthma - Dormant Projects (Contd..9), H2 2016
Asthma - Dormant Projects (Contd..10), H2 2016
Asthma - Dormant Projects (Contd..11), H2 2016
Asthma - Dormant Projects (Contd..12), H2 2016
Asthma - Dormant Projects (Contd..13), H2 2016
Asthma - Dormant Projects (Contd..14), H2 2016
Asthma - Dormant Projects (Contd..15), H2 2016
Asthma - Dormant Projects (Contd..16), H2 2016
Asthma - Dormant Projects (Contd..17), H2 2016
Asthma - Dormant Projects (Contd..18), H2 2016
Asthma - Dormant Projects (Contd..19), H2 2016
Asthma - Dormant Projects (Contd..20), H2 2016
Asthma - Dormant Projects (Contd..21), H2 2016
Asthma - Dormant Projects (Contd..22), H2 2016
Asthma - Dormant Projects (Contd..23), H2 2016
Asthma - Dormant Projects (Contd..24), H2 2016
Asthma - Dormant Projects (Contd..25), H2 2016
Asthma - Dormant Projects (Contd..26), H2 2016
Asthma - Dormant Projects (Contd..27), H2 2016
Asthma - Dormant Projects (Contd..28), H2 2016
Asthma - Dormant Projects (Contd..29), H2 2016
Asthma - Dormant Projects (Contd..30), H2 2016
Asthma - Dormant Projects (Contd..31), H2 2016
Asthma - Dormant Projects (Contd..32), H2 2016
Asthma - Dormant Projects (Contd..33), H2 2016
Asthma - Dormant Projects (Contd..34), H2 2016
Asthma - Dormant Projects (Contd..35), H2 2016
Asthma - Dormant Projects (Contd..36), H2 2016
Asthma - Discontinued Products, H2 2016
Asthma - Discontinued Products (Contd..1), H2 2016
Asthma - Discontinued Products (Contd..2), H2 2016
Asthma - Discontinued Products (Contd..3), H2 2016
Asthma - Discontinued Products (Contd..4), H2 2016
Asthma - Discontinued Products (Contd..5), H2 2016
Asthma - Discontinued Products (Contd..6), H2 2016
Asthma - Discontinued Products (Contd..7), H2 2016
Asthma - Discontinued Products (Contd..8), H2 2016 720

LIST OF FIGURES

Number of Products under Development for Asthma, H2 2016
Number of Products under Development for Asthma - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Number of Products under Investigation by Universities/Institutes, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Products, H2 2016
Assessment by Monotherapy Products, H2 2016
Assessment by Combination Products, H2 2016
Number of Products by Top 10 Targets, H2 2016
Number of Products by Stage and Top 10 Targets, H2 2016
Number of Products by Top 10 Mechanism of Actions, H2 2016
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
Number of Products by Top 10 Routes of Administration, H2 2016
Number of Products by Stage and Top 10 Routes of Administration, H2 2016
Number of Products by Top 10 Molecule Types, H2 2016
Number of Products by Stage and Top 10 Molecule Types, H2 2016
Skip to top


Allergic Asthma - Pipeline Review, H2 2016 US$ 2,000.00 Aug, 2016 · 181 pages
Asthma - Pipeline Review, H1 2016 US$ 2,125.00 Apr, 2016 · 772 pages
Allergic Asthma - Pipeline Review, H1 2016 US$ 1,700.00 Feb, 2016 · 182 pages
Allergic Asthma - Pipeline Insights, 2016 US$ 1,000.00 Nov, 2016 · 60 pages
Chronic Asthma - Pipeline Insights, 2016 US$ 1,000.00 Nov, 2016 · 60 pages

Ask Your Question

Asthma - Pipeline Review, H2 2016
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: